Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more ...

On 03 September 2025, Hoffmann-La Roche conducted a study is to assess the long-term safety and to explore the efficacy of ...

Users of the omnipresent pills compare them to Oxycodone or Vicodin — but with even bigger highs and tougher withdrawals.

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1)Planning ...

NetworkNewsWire Editorial Coverage NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies ...

I'm very happy to be here with the CEO of Rezolute, Nevan Elam. This is Kelly McCarthy from the Morgan Stanley Healthcare team and really excited to have you at our conference. I know you got a great ...

Systemic lupus erythematosus is a clinically and immunologically heterogenous, systemic autoimmune disease characterized by ...

A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes ...

Vince Sanders, president and founder of locally based CBD American Shaman, spent the past decade turning hemp oil and other ...

Curious about the latest updates in the Fibromyalgia Pipeline? Click here to explore the therapies and trials making ...

Denifanstat met all primary and secondary endpoints versus placeboDenifanstat was generally well toleratedSagimet initiated first-in-human Phase ...